Phaseline

Companies › CRISPR Therapeutics

CRISPR Therapeutics: clinical trials, targets and expected readouts

4 active drug programs in 5 registered trials: 5 Phase 1; Hematology, Oncology, Cardiovascular, Immunology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CTX310
In vivo CRISPR-Cas9 gene editing targeting ANGPTL3
ANGPTL3Phase 1CardiovascularJun 2027
CTX340
CRISPR-Cas9 therapy targeting angiotensinogen (AGT) gene disruption in liver
AGTPhase 1HypertensionJul 2028
CTX112 (Zugocabtagene geleucel, zugo-cel)
CD19-directed CAR-T cell therapy; allogeneic T cells genetically modified using CRISPR-Cas
CD19Phase 1B-cell Lymphoma; Warm Autoimmune Hemolytic Anemia (WAIHA)Jan 2030
CTX112
CD19-directed allogeneic T-cell therapy with CRISPR-Cas9 gene editing
CD19Phase 1SLE (Systemic Lupus)Dec 2031

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07491172CTX310Phase 1CardiovascularMetabolic and endocrineJun 2027
NCT07758634CTX340Phase 1HypertensionCardiovascularJul 2028
NCT05643742CTX112 (Zugocabtagene geleucel, zugo-cel)Phase 1B-cell LymphomaOncologyJan 2030
NCT06925542CTX112Phase 1SLE (Systemic Lupus)ImmunologyDec 2031
NCT07549698CTX112 (Zugocabtagene geleucel, zugo-cel)Phase 1Warm Autoimmune Hemolytic Anemia (WAIHA)HematologyDec 2033

From the company's SEC filings

Cash and short-term investments of $2.3bn on 2026-09-30; operating cash outflow about $379m a year; runway about 72 months at that burn, to Sep 2032

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

CD19 (2) AGT (1) ANGPTL3 (1)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Allogene Therapeutics Miltenyi Biomedicine Amgen AstraZeneca Beijing Yongtai Ruike Biotechnology Company Shanghai Ming Ju Biotechnology iCell Gene Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.